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Introduction
The last session of the conference on Environmental
Mutagenesis in HumanPopulations atRisk was devoted to
a panel discussion. The chairpersons ofthe panel were J.
Ashby and A. Massoud. The moderator was J. Gentile and
the panel members were R. Albertini, D. DeMarini, S. El
Ghazali, R. Faris, A. T. Natarajan, Z. Riad, A. Salam, A.
Shawky, M. Sorsa, R. Tennant, and M. Waters. The panel
was charged with providing an overall conclusion of the
conference and recommendations for future directions in
the field of environmental and genetic toxicology with
emphasis for developing countries. Enthusiastic exchange
of ideas and suggestions were made among the panelists
andbetweenthe audience andthepanelists. Theobjectives
of the discussion session were accomplished, and a sum-
mary ofthe discussion is presented here. The conclusions
specifically address some crucial environmental and
human-health problems that are encountered in develop-
ing countries such as Egypt and emphasize the need for
both local and international centers of coordination. Such
coordination is usually assumed to be the responsibility of
government agencies, but its absence is a reality. Without
such coordination, efforts to address problems with
environmental mutagens are often duplicated or wasted.
Such questions came to the fore at the Cairo meeting
both because manydeveloping countries wererepresented
and because the focus of the meeting was specifically
oriented toward populations at risk, rather than to chemi-
cal mutagens per se. Specifically, it was felt that advances
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in the technology associated with the detection and
assessment of environmental carcinogens and mutagens
should be accompanied by progress in the planning and
optimal deployment of these techniques, especially in
developing countries. At present, we are moving toward a
situation where advanced techniques are used in a seem-
ingly random and probably suboptimal way. The six areas
considered worthy ofinternational and national coordina-
tion are discussed below.
General Toxicology of Chemicals
Mutagenicity and carcinogenicity are highly regarded
as toxic effects because they can occur in the absence of
othertoxiceffects andlongafterexposure.Althoughthese
concerns are valid, they should not preclude the assess-
ment ofother more proximal toxicities. Thus, the possible
teratogenicity, immunotoxicity, or embryotoxicity of a
chemical should be considered with mutagenicity/carcino-
genicitydatawhenassessingoverallhazard. Moreevident
acute toxicities such as the sensitizing potential of an
agentmay, infact, force human exposure levels so lowthat
anylonger term toxicities can be discounted. Such consid-
erations canonlybemade on achemical-by-chemicalbasis.
In situations where the toxicityofa chemical is completely
unknown, assessment ofits mutagenicity, using the stan-
dard Salmonella mutation assay, is probably the most
effective first study to conduct.
Hazard Prioritization
Chemical mutagenesis and carcinogenesis is but one
possible human hazard in a given country or environment.
Action on such agents should therefore proceed as part of
an awareness of the major sources of pollution/disease.
Once the relative priority of chemical mutagens as a
hazard has been ascertained, the major sites and sources
ofchemical pollution should be identified. After this, con-
sideration should be given to the practicality, costs, and
benefits of taking remedial action. For example, quiteASHBY ET AL.
different actions might be taken upon discovering a natu-
ral mutagen in a stable food supply as opposed to the
realization that a replaceable mutagenic chemical is being
used as a fungicide in food storage hoppers. In cases
where a priority for action emerges and when immediate
protective measures cannot be instituted, consideration
should be given to the most appropriate human sur-
veillance technique to use. Thus, havingidentified amuta-
genic pollutant that may adversely affect human health, it
would be considered more appropriate in some circum-
stances to mount a limited human surveillance study (to
assess the likely extent ofthehazard)ratherthanconduct
full-scale animal or cell-based mutagenicity tests on the
agent.
In the absence of such coordination, scarce resources
maybewasted, forexample, on studyingthemutagenicity
ofmutagenAtomicroorganismswhilehumanexposure to
mutagenB continuesunabatedbecause oflackofadequate
knowledge of relative human hazards. The problems
inferred in this part ofthe analysis are illustrated by the
factthatitis often lefttoindividual scientists to seekouta
hazardous chemical, to test it, and then to alert the
relevantauthorities aboutitsproperties. Thisishardlythe
best way to prioritize hazards or to use time. Itwould be
more effective for scientists to offer a resource for use in
areas identified independently as presenting a maximum
human hazard.
Another major advantage ofcentralizing the process of
hazard recognition and hazard prioritization is that haz-
ards can be integrated with precise measurements of
human exposure, which can contribute significantly to
recognizing human hazards. These measurements may
then, for example, lead to priority action against a weak
mutagen towhich humans are chronicallyexposed athigh
dose levels, despite the presence ofmore potentmutagens
with no human exposure in the same environment. An
instance of a failure to rank hazards was provided by the
extensive international debate on the possible carcino-
genic hazard ofnitrosation ofcarbaryl, although the most
likelyhuman hazard was associatedwith thevolatile toxin
methyl isocyanate used in its manufacture.
Afurtherpointis that aregulatory stancehas nowbeen
taken inthewesternworld on mostcommoditychemicals/
pesticides/herbicides, etc. Such regulatory positions can
provideausefulprimaryassessmentofagivenchemicalin
a newenvironment and should be taken into consideration
by all countries. Local conditions ofuse may modify that
initial assessment, but the alternative of ignoring the
response ofothercountries tothe samechemical shouldbe
discouraged.
Chemical Prioritization
When attempting to assess the possible impact of
environmental mutagens/carcinogens on human health, it
is important to knowsomething ofthe range ofpollutants
present. Named pollutants (e.g., pesticides) are easy to
recognize, buttheymay notbe the mostimportant agents
present. Most agencies decide that endogenous mutagens
must be tolerated and that emphasis should be placed on
the detection and assessment of man-made pollutants.
This is acceptable so long as the implicit compromise of
acceptable riskis recognized. Sometimes this compromise
may be unacceptable, as in an environment known to be
richinnaturalnitrosamines; however, suchknowledgecan
only come from an evalution ofchemical pollutants.
Inspecting the chemical structure ofan agent for sites
of actual or potential electrophilicity provides a useful
primary screen for agents with an enhanced chance of
being mutagenic and/or carcinogenic to several species,
including humans. Such an analysis can be based on
chemical knowledge or can be assisted by computerized
structure-activity systems. Such structural alerts, how-
ever, onlyprovide anindicationfortheneedtoevaluatethe
toxicity of an agent. They do not remove the need to
conduct such tests.
The U.S. Environmental Protection Agency and the
InternationalProgramme on Chemical Safetyare sources
oftoxicity/mutagenicity data on major commodity chemi-
cals. In addition, the European Chemical Industry Ecol-
ogy and Toxicology Center has published a survey ofover
2000 chemicals whose toxic status has been reviewed by
one ormore agencies (1). Onthe otherhand, suppliersmay
be the only source of data on new chemicals. Only when
sources ofdatahavebeenexhausted should newstudiesbe
commissioned on a chemical. In cases where additional
mutagenicity data are required before a hazard assess-
mentcanbemade, itispreferable tobuild these studies on
the internationally agreed base of assays in Salmonella
and for clastogenicity in cultured mammalian cells. Thus,
the initial assessment ofa chemical in plant assays, yeast,
Drosophila or other similar systems should be dis-
couraged.
Rodent cancer data can be obtained from among the
InternationalAgencyfor Research on Cancerlists, Gold's
TD50 database (2), the U.S. National Toxicology Program
carcinogen database, orfromthe suppliers ofchemicals in
the case of major products. Finally, updated information
can also be obtained from the current scientific literature.
From such an analysis, it is usuallypossible to assess the
mutagenic/carcinogenic hazard of an agent without addi-
tionaltesting. Suchprecautionarysearcheswillenablethe
limited resources available in developing countries to be
used on agents ofimportance to the environment and for
which no data exist. Unfortunately, it is common to find
scarce resources in a developing country for evaluating a
chemical ab initio, even when the agent is of known
genotoxicity in developed countries and the chemical may
even be banned or controlled in those countries.
The question of chemical mixtures is an ever-present
problem in all countries. Not only may synergistic or
antagonisticeffectsbeproducedinmixtures,butgenotoxic
effects considered negligible on an individual chemical
basis may become significantwhen integrated into a mix-
ture. Documentationofmutageniceffectsinexposedpopu-
lations and assessment ofthemutagenicity ofrepresenta-
tive mixtures derived from an environment can provide
inputto hazard ranking, althoughinternationalresponses
336GENETIC TOXICOLOGY: COMMENTS AND RECOMMENDATIONS
to data on mixtures remain unclear.
Prioritization ofchemicalhazards commenceswithpub-
lished information. Additional mutagenicity experiments
and human surveillance studies flow from such analysis,
but should not replace them. These considerations are of
great importance in countries with limited resources and
withperhaps more importanthumanhealthproblems that
must be addressed.
Human Surveillance Studies
A wide variety of techniques for monitoring genetic
damageinducedin humansbyenvironmental chemicals or
environmental factors are now available. Rapid advances
in improving the sensitivity of such techniques are being
made, and these were reviewed at the conference. During
the conference, emphasis was placed on the proper use of
these techniques, and the following points emerged:
a)Populationsselectedforstudyshouldbeinfluencedby
a clear perception of the relative hazards in the given
country or environment.
b) Specific attention shouldbegiven totheexperimental
designofstudies,inparticular,theselectionofappropriate
and concurrent control groups, the choice of adequate
group sizes, the elimination ofconfounding variables, the
use of coded samples for analysis, and the selection of
vigorous statistical methods for the evaluation ofdata.
c) Attempts should be made, wherever possible, to
include anintervention aspectto the study(e.g., the study
ofindividuals before they enter the polluted environment,
the follow-up of those who leave it, and monitoring the
effect ofselective removal ofa suspect genotoxin from the
environment under study).
d) The use of cytogenetic analysis in all studies on
human blood is strongly recommended. This will enable a
common point ofcomparison between studies using other
end points (e.g., hemoglobin adducts, hprt mutations, sis-
ter chromatid exchange) and between studies performed
in different countries and in time.
e) The current progress in human surveillance tech-
niques suggests that refined methodologies will soon be
available, and it will be important to reassess earlier
studies using these new techniques. It is suggested that
bloodsamples shouldbestoredfromallstudiesforfurther
analysis. The possible role ofthe World Health Organiza-
tion (WHO) and the Red Cross in this task should be
explored.
f) The possible role of lifestyle variables such as defi-
cient diet, food contaminants and infection in modulating
genetic outcome from exposure to mutagens is ofparticu-
lar importance in developing countries.
Insummary,whenamajorgenetichazardisrecognized,
an important consequence is usually that the exposed
humanswill bemonitored toquantifythathazard. In such
cases, great care should be taken to optimize the derived
data by adequately designing the studies. Human sur-
veillance studies are the last point ofintervention before
the recognition of human disease via epidemiological/
clinical observations-as such they deserve appropriate
designandfollow-up.Atpresent,humansurveillancestud-
ies tend to be conducted on limited budgets and at the
discretion of individual investigators. The study of
ethylene-oxide-exposed cohorts by Tates and his col-
leagues (3) represents an excellent model of a successful
human surveillance study.
Long-Term Follow-up of Human
Studies
Implicit in the use of human surveillance (genetic
monitoring) techniques is that acutely induced genetic
changes provide an indication of possible long-term car-
cinogenic or mutagenic effects. Although this provides a
practical and conservative justification for such studies,
there are few data to support the underlying assumption.
Ageneral conclusion oftheconferencewas, therefore, that
attempts shouldbemade toinitiate appropriatelong-term
follow-up studies-specifically, that epidemiological
methods be used to correlate the outcome of surveillance
studies with eventual onset ofdisease.
Alternatively,insomecaseswhereapopulationisidenti-
fied as being exposed to a possible mutagen/carcinogen,
bloodsamples couldbestoredforpossiblefutureuseinthe
case of a subsequent epidemiological study revealing an
increased cancer incidence in that population. In the
absence of such follow-up studies, the present human
surveillance methods will have to remain simply as a
means to indicate potential long-term health effects. The
necessary follow-up studies will require the backing and
administrative assistance ofa central body such asWHO
or IPCS: the conference unanimously endorsed the need
for such an initiative. The further possible initiative of
mounting prospective mutation epidemiology was
accepted as being currently impractical; reliance will
therefore have to be on data currently collected, such as
abortion and cancer incidences.
An extension of the above discussion is the fact that
ethical issues are raised by the conduct of human sur-
veillance studieswithoutadequatefollow-upstudies.Thus,
if the implied stimulus for mounting such a human sur-
veillance studyistheneed torecognize andcontrolhuman
exposure to a potential human carcinogen/mutagen,
actions should flow from the observation of a positive
effect. At present, such actions often do notfollow, simply
because the significance to the individual of the positive
surveillancedataisnotclear.Carefullyconstructedfollow-
up studies would break this circle ofuncertainty.
Need for International Coordination
All countries haveregulatoryauthoritieswhose respon-
sibilityistomonitorthesafetyofkeyimportedordomestic
chemicals such as pesticides and herbicides. Often these
authorities consider onlypotential new registrations. It is
therefore easy for the situation to develop wherein
extreme attention ispaid to afew newchemicals while the
many thousands of existing environmental chemicals are
essentially ignored, unless arbitrarily selected for study
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by individual investigators. A pressing need, therefore, is
for a central agency in each country to be responsible for
assessing the relative hazards in the environment and for
prioritizing chemicals for study. Ideally, individual muta-
genicity studies and human surveillance studies should be
conducted considering these countrywide priorities. Fur-
ther, there is an evidentrole forinternational coordination
ofinformation onthemajorchemicals ofcommerce,includ-
ingagrochemicals, pesticides, andherbicides. Decisions to
use a particular chemical will vary depending on local
needs, but the toxicological profile of such chemicals
should be internationally available as a primary input to
such decisions.
Conclusions
There is a need for a standard and internationally
available toxicological profile on all major man-made
environmental chemicals. There is an equal need for both
national and international coordination of human sur-
veillance studies in cases where people are exposed to a
knowncarcinogen ormutagen atlevelsconsidered likelyto
induce significant genetic effects. Finally, at the national
level, itis necessary to consider the relative importance to
human health ofdiscrete chemical mutagens and carcino-
gens. Thesebroadrecommendations areconsideredneces-
saryto ensure conservation oflimited resources and their
focusing on problems whose solution might effectively
benefit human health. At present, it is not unusual for
resources to be dissipated in studying, ab initio, the
mutagenicity ofchemicals whose toxicology is well estab-
lished in other countries; some such chemicals would
probablyalsofigurelowonthelistofprioritiesforactionin
the country in question, once such a priority list existed.
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